Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human Study of [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G in Pancreatic Cancer
NCT04665947Phase 1Active, not recruiting
- Sponsor
- University of California, Davis
- Start
- Dec 2020
- Primary completion
- Jul 2027
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of lutetium lu 177-dota-abm-5g in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by University of California, Davis. Primary endpoints: [68Ga]Ga DOTA-5G PET/CT imaging at 2 hours and [177Lu]Lu DOTA-ABM-5G dose escalation therapy at 30 days. Started Dec 2020; status: active, not recruiting.
02
Drugs
lutetium lu 177-dota-abm-5g
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04665947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04665947.